Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Chemistry & Biology|June 25, 2011
In situ kinase profiling reveals functionally relevant properties of native kinasesMatthew P Patricelli, Tyzoon K Nomanbhoy, Jiangyue Wu, et al.Proceedings of the National Academy of Sciences of the United States of America|March 9, 2011
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathwaysTsui-Fen Chou, Steve J Brown, Dmitriy Minond, et al.Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.Nature Chemical Biology|September 13, 2022
Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteineMadeline E Kavanagh, Benjamin D Horning, Roli Khattri, et al.The Journal of Biological Chemistry|January 7, 2012
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kineticsQingsong Liu, Sivapriya Kirubakaran, Wooyoung Hur, et al.Blood|May 7, 2016
Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphomaJulie Marie Matthews, Shruti Bhatt, Matthew P Patricelli, et al.Cancer Research|February 26, 2013
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATRQingsong Liu, Chunxiao Xu, Sivapriya Kirubakaran, et al.Journal of Medicinal Chemistry|September 18, 2025
Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High CancersShota Kikuchi, Jason C Green, Don C Rogness, et al.Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.Nature|April 24, 2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicaseKristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.Pageof 4